Summary:
Atalanta Therapeutics has secured $97 million in Series B funding to advance its innovative RNA interference therapies targeting brain disorders. The company is developing treatments for Huntington’s disease and genetic epilepsy, utilizing specialized RNA delivery to the brain.
Summary:
Sage Therapeutics has rejected Biogen’s $469 million takeover offer, stating it undervalues the company. While exploring strategic alternatives, Sage continues focusing on Zurzuvae, its postpartum depression drug co-marketed with Biogen.
Summary:
The FDA has expanded Enhertu’s approval to include breast cancers with ultralow HER2 expression, allowing earlier treatment before chemotherapy. The drug, developed by AstraZeneca and Daiichi Sankyo, showed significant improvement in delaying cancer progression.
Summary:
Helicore Biopharma launches with $65 million in Series A funding to develop GIP-targeting antibodies for obesity treatment. The company’s lead candidate, HCR-188, aims to achieve higher-quality weight loss by preserving lean muscle mass.
Summary:
2025 kicks off with robust pharma M&A activity, highlighted by J&J’s $14.6B intra-cellular deal. The industry holds $1.3T in deal potential, though high premiums and margin pressures may impact future transactions.
